ERBB2 and neoplasm: In the past 10 years, we and other laboratories have shown that anti-EGFR, anti-HER2, anti-CD20, and anti-CD47 in combination with immune checkpoint blockade could have synergistic effects in host adaptive anti-immune responses and tumor eradication.